Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • A Spanish biotech banks $87M to make differentiated ADCs
  • M&A / Deals

A Spanish biotech banks $87M to make differentiated ADCs

BioPharma Dive

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.

Oncology

Read full story

pharminent June 4, 2026 (Last updated: June 4, 2026)

BioPharma Dive

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.

Oncology

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Legend surges on early data for ‘in vivo’ lymphoma cell therapy
Next: Cellares and TScan to assess automated manufacturing of TSC-101 therapy

Related Stories

  • M&A / Deals

Supernus and Indivior merge to create CNS mega-company with 11 approved drugs

pharminent August 3, 2026
  • M&A / Deals

J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout

pharminent July 31, 2026
  • M&A / Deals

Eisai and CORE Biomedicine agree on global licence for oncology pipeline

pharminent July 29, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.